

Winald R Gerritsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7712827/publications.pdf>

Version: 2024-02-01

33
papers

5,543
citations

471509

17
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

8077
citing authors

#	ARTICLE	IF	CITATIONS
1	Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. <i>Clinical Cancer Research</i> , 2022, 28, 1572-1585.	7.0	36
2	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	7.0	21
3	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolimmunology</i> , 2022, 11, .	4.6	3
4	Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4532-4532.	1.6	32
5	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
6	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. <i>Cancers</i> , 2021, 13, 4660.	3.7	2
7	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , 2020, 25, e1-e4.	3.7	9
8	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020, 25, e1428-e1432.	3.7	3
9	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	3.2	25
10	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	83
11	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
12	Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.. <i>Journal of Clinical Oncology</i> , 2020, 38, 121-121.	1.6	3
13	Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1374-1385.	3.0	6
14	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1179-1185.	2.3	9
15	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1051-1061.	1.6	174
16	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1579-1587.	1.6	97
17	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	4.8	107
18	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 344-344.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 410-410.	1.6	19
20	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	27.0	2,677
21	Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging. European Urology, 2017, 71, 93-95.	1.9	2
22	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 40-47.	1.6	577
23	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4501-4501.	1.6	17
24	Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).. Journal of Clinical Oncology, 2017, 35, 9523-9523.	1.6	18
25	Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.. Journal of Clinical Oncology, 2017, 35, 9540-9540.	1.6	0
26	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	4.4	10
27	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology, 2016, 5, e1191732.	4.6	17
28	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology, 2016, 5, e1057673.	4.6	67
29	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. Journal of Clinical Oncology, 2016, 34, 330-330.	1.6	1
30	Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. Journal of Clinical Oncology, 2016, 34, 329-329.	1.6	0
31	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2014, 15, 700-712.	10.7	1,280
32	Differential Effects of Combined Ad5- β 24RGD and Radiation Therapy in <i>In vitro</i> versus <i>In vivo</i> Models of Malignant Glioma. Clinical Cancer Research, 2007, 13, 7451-7458.	7.0	47
33	Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research, 2002, 62, 5736-42.	0.9	142